“There are frustratingly few tools available today to help the seriously ill patient with pulmonary embolism. Having now treated over 35 PE patients with the EKOS system within the past 2 years, I have adopted EKOS as our standard of care; a valuable addition to our armamentarium for pulmonary embolism.”
pulmonary hypertension, and death. Up to 22% of these patients will die within 90 days. The EKOS EkoSonic® System provides a new life saving therapy for these patients. Until now, drugs were the only approved treatment.

Prof. Nils Kucher from the University Hospital of Bern (Switzerland), principal investigator of the Ultrasound Accelerated Thrombolysis of Pulmonary Embolism (ULTIMA) trial launched in 2010, emphasized, “Because the EKOS system incorporates into the catheter body small ultrasound transmitters which condition the clot to more rapidly absorb the thrombolytic drug, it can dissolve the clot faster than thrombolytic drug alone.

Dr. Tod Engelhardt, cardiothoracic surgeon from East Jefferson General Hospital (New Orleans, LA) added that, "Faster response with less thrombolytic drug means patients may recover within hours and the risk of bleeding is substantially reduced." I've treated 30 patients with the EKOS system. All have done remarkably well and I know we have saved lives. The patients treated were all in serious condition and within a few hours of commencing treatment were asymptomatic."

Dr. Peter Lin, vascular surgeon from Baylor College of Medicine (Houston, TX) commented, "There are frustratingly few tools available today to help the seriously ill patient with pulmonary embolism. Having now treated over 35 PE patients with the EKOS system within the past 2 years, I have adopted EKOS as our standard of care; a valuable addition to our armamentarium for pulmonary embolism."

Robert W. Hubert, President/CEO concluded that, “Since 2004, the EKOS system has been cleared for use by the U.S. FDA and European authorities for use in clearing blood clots in the arms and legs. EKOS pursued CE Mark for treating PE based on receiving positive results from physicians treating these patients with the EkoSonic® system, along with several centers publishing their findings in peer reviewed journals."

**About EKOS Corporation:** EKOS Corporation pioneered the development and clinical application of ultrasound infusion technologies in medicine, introducing its first system for the treatment of vascular thrombosis in 2005. Today, interventional radiologists, cardiologists, cardiothoracic and vascular surgeons at leading institutions around the world use the EKOS EkoSonic® Endovascular System to provide faster, safer and more complete dissolution of thrombus. The EkoSonic System is FDA-cleared for controlled and selective infusion of physician-specified fluids, including thrombolytics, into the peripheral vasculature. Visit [www.ekoscorp.com](http://www.ekoscorp.com).

**Contacts**
PMT Healthcare Marketing, Inc.
Pauline T. Mayer, 631-979-3780
PTM@ptmhcm.com